Literature DB >> 18983885

Oxidative stress and cognitive ability in adults with Down syndrome.

Andre Strydom1, Mark J Dickinson, Simadevi Shende, Domenico Pratico, Zuzana Walker.   

Abstract

AIMS: We aimed to study the hypothesis that high levels of superoxide dismutase (SOD1), previously reported in Down syndrome, would be associated with poorer ability on cognitive tests. Compensatory rises in the activity of glutathione peroxidase (GPx) was expected to be associated with better ability, so that a high ratio between SOD1 and GPx was hypothesised to be the best predictor of poorer cognitive performance.
METHODS: 32 adults with Down syndrome between the ages of 18 and 45 years donated blood samples for SOD1 and GPx assays and urine for Isoprostane 8,12-iso-iPF(2alpha)-VI assay, a specific biomarker of lipid peroxidation in vivo. Informants rated functional ability and memory function for all participants, and those adults with DS that was able to, also completed psychometric assessments of language ability and memory.
RESULTS: Neither SOD1 nor GPx were related to the elevated markers of lipid peroxidation previously described in living adults with DS, and our hypothesis that an increased SOD1/GPx ratio would be correlated with worse performance on cognitive or functional measures was not supported. Contrary to our hypothesis, we found that low SOD1/GPx ratios were associated with worse memory ability, which remained after controlling for confounders such as sex, age or nutritional supplements.
CONCLUSIONS: The anti-oxidant system in DS is implicated in the cognitive phenotype associated with the chromosomal disorder, but the variations in the phenotype could result from several possible gene or gene product interactions. Much further research is required before it will be possible to counteract the oxidative stress associated with DS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18983885     DOI: 10.1016/j.pnpbp.2008.10.006

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  21 in total

1.  Phagocytic cell activity and periodontitis in Down syndrome.

Authors:  A Khocht; B Russell; J G Cannon; B Turner; M Janal
Journal:  Oral Dis       Date:  2011-11-29       Impact factor: 3.511

2.  Reactive oxidative species enhance amyloid toxicity in APP/PS1 mouse neurons.

Authors:  Bin Yang; Xiaqin Sun; Hilal Lashuel; Yan Zhang
Journal:  Neurosci Bull       Date:  2012-06       Impact factor: 5.203

Review 3.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

4.  Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation.

Authors:  Ira T Lott; Eric Doran; Vinh Q Nguyen; Anne Tournay; Elizabeth Head; Daniel L Gillen
Journal:  Am J Med Genet A       Date:  2011-07-07       Impact factor: 2.802

5.  Alzheimer-Related Cerebrovascular Disease in Down Syndrome.

Authors:  Patrick J Lao; José Gutierrez; David Keator; Batool Rizvi; Arit Banerjee; Kay C Igwe; Krystal K Laing; Mithra Sathishkumar; Fahmida Moni; Howard Andrews; Sharon Krinsky-McHale; Elizabeth Head; Joseph H Lee; Florence Lai; Michael A Yassa; H Diana Rosas; Wayne Silverman; Ira T Lott; Nicole Schupf; Adam M Brickman
Journal:  Ann Neurol       Date:  2020-10-09       Impact factor: 10.422

Review 6.  Antioxidants in Down syndrome.

Authors:  Ira T Lott
Journal:  Biochim Biophys Acta       Date:  2011-12-21

7.  Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome phenotypes.

Authors:  Jennifer Keck-Wherley; Deepak Grover; Sharmistha Bhattacharyya; Xiufen Xu; Derek Holman; Eric D Lombardini; Ranjana Verma; Roopa Biswas; Zygmunt Galdzicki
Journal:  Dev Neurosci       Date:  2011-10-27       Impact factor: 2.984

Review 8.  Neurological phenotypes for Down syndrome across the life span.

Authors:  Ira T Lott
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

9.  Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.

Authors:  Adviye A Tolun; Peter M Scarbrough; Haoyue Zhang; Jane-Ann McKillop; Frances Wang; Priya S Kishnani; David S Millington; Sarah P Young; Dora Il'yasova
Journal:  Ann Epidemiol       Date:  2012-10-11       Impact factor: 3.797

10.  Oxidative burst intensity of peripheral phagocytic cells and periodontitis in Down syndrome.

Authors:  A Khocht; B Russell; J G Cannon; B Turner; M Janal
Journal:  J Periodontal Res       Date:  2013-03-14       Impact factor: 4.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.